Beyond ruxolitinib: fedratinib and other emergent treatment options for myelofibrosis
JP Bewersdorf, SM Jaszczur, S Afifi… - Cancer Management …, 2019 - Taylor & Francis
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal proliferation of
differentiated myeloid cells leading to bone marrow fibrosis, cytopenias and extramedullary …
differentiated myeloid cells leading to bone marrow fibrosis, cytopenias and extramedullary …
miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype
EJ Cuenca‐Zamora, PJ Guijarro‐Carrillo… - American Journal of …, 2024 - Wiley Online Library
Emerging evidence shows the crucial role of inflammation (particularly NF‐κB pathway) in
the development and progression of myelofibrosis (MF), becoming a promising therapeutic …
the development and progression of myelofibrosis (MF), becoming a promising therapeutic …
[HTML][HTML] Graft detachment after Descemet's stripping automated endothelial keratoplasty in bullous keratopathy and Fuchs dystrophy
N Cardascia, V Pastore, V Bini… - … and Innovation in …, 2020 - ncbi.nlm.nih.gov
Descemet's stripping automated endothelial keratoplasty (DSAEK) is a surgical technique
for corneal transplantation in case of corneal decompensation. One of the main …
for corneal transplantation in case of corneal decompensation. One of the main …
OPEN ACCESS EDITED BY
EO Leibundgut, S Hermouet, N Angers… - Myeloproliferative …, 2024 - books.google.com
OPEN ACCESS EDITED BY Page 52 frontiers TYPE Mini Review Frontiers in Oncology
PUBLISHED 22 May 2023 DOI 10.3389/fonc. 2023.1196817 Check for updates OPEN …
PUBLISHED 22 May 2023 DOI 10.3389/fonc. 2023.1196817 Check for updates OPEN …
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
R Ayala, RA Fernández, V García‐Gutiérrez… - …, 2023 - Wiley Online Library
This phase Ib, non‐randomized, open‐label study evaluates the safety and tolerability of
ruxolitinib in combination with nilotinib and prednisone in patients with naïve or ruxolitinib …
ruxolitinib in combination with nilotinib and prednisone in patients with naïve or ruxolitinib …
Case report: Double L611S/V617L JAK2 mutation in a patient with polycythemia vera originally diagnosed with essential thrombocythemia
X Li, J Liu, C Liu - Frontiers in Oncology, 2022 - frontiersin.org
Double JAK2 mutations have rarely been described in myeloproliferative neoplasms (MPNs)
and are demonstrated to be associated with the polycythemia vera (PV) phenotype. Here …
and are demonstrated to be associated with the polycythemia vera (PV) phenotype. Here …
Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
L Huo, J Xie, Q Wang, H Shen, Z Ding… - Clinical Case …, 2023 - Wiley Online Library
Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR
mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene …
mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene …
Prognostische Biomarker und neue Therapieoptionen bei seltenen myeloischen Neoplasien
J Lübke - 2021 - archiv.ub.uni-heidelberg.de
Seit der reformierten Konsensusklassifikation der World Health Organization von 2016 wird
die systemische Mastozytose aufgrund ihrer klinischen und pathologischen Heterogenität …
die systemische Mastozytose aufgrund ihrer klinischen und pathologischen Heterogenität …
[PDF][PDF] Frecuencia de la mutación JAK2 V617F en pacientes con neoplasias mieloproliferativas en SOLCA-Cuenca en el periodo 2015–2019
GIJ Murillo, CFO Anguisaca, GDB Ordoñez - 2021 - dspace.ucuenca.edu.ec
ANTECEDENTES Las neoplasias mieloproliferativas son un conjunto de trastornos clonales
hematológicos originados por variantes patogénicas en genes reguladores del crecimiento …
hematológicos originados por variantes patogénicas en genes reguladores del crecimiento …
Síntesis de derivados de 4-hidroxi-6-metil-2-pirona potencialmente bioactivos
SZ Gutiérrez Ravelo - 2020 - riull.ull.es
La enzima JAK-2 es una proteína tirosina kinasa que interviene en procesos tumorales,
inflamatorios e inmunitarios. Una mutación en esta enzima provoca enfermedades raras …
inflamatorios e inmunitarios. Una mutación en esta enzima provoca enfermedades raras …